Aptar Pharma Completes First Phase of Global Expansion Program

The investments will add new digitalized processes and expand the company’s manufacturing capacity to meet growing customer needs.

Aptar Pharma New Facility Granville With Caption

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

Aptar Pharma has delivered the first phase of its previously announced expansion program of approximately $180 million to meet growing customer capacity needs for injection system solutions.

The multisite, international expansion project began in 2020 and is intended to significantly boost capacity across all product lines, ultimately enabling Aptar Pharma to produce over 10 billion injectable component units annually when completed.

Aptar Pharma’s investment encompasses the expansion and ramping up of Aptar Pharma manufacturing of PremiumCoat® ETFE film-coated components, PremiumFill® enhanced specification solutions, elastomer components, and vial stoppers worldwide. The expansion program includes investments in France and the U.S., adding an additional 23,000+ square meters of manufacturing footprint. The first phase of the PremiumCoat® capacity expansion is already operational in Granville, France, and includes new ISO7 clean rooms and advanced robotics.

An additional factory in Granville, France, will be operational in early 2024. The establishment of a second manufacturing facility in Granville paves the way for a step change in capacity and high-tech efficiency for Aptar. The highly automated factory will significantly increase production capacity to meet growing demand for elastomeric components, including PremiumCoat® solutions for enhanced drug/container compatibility.

U.S.-based manufacturing capabilities will also be operational as of 2024 to better serve the local market. Further manufacturing expansion phases in both the U.S. and France are included in the program.

To meet the ever-increasing market and customer requirements for higher quality and reliability, Aptar Pharma is expanding its capabilities with robotization, digitalization, and new clean rooms. Sustainability is a major consideration in Aptar Pharma’s expansion program, with the implementation of solar power production, water waste management, and optimized energy consumption included.

Fill out the form below to request more information about Aptar Pharma Completes First Phase of Global Expansion Program